Abstract
The antithrombotic therapy is an important part of medical treatment in percutaneous coronary interventions (PCI). The so called dual antiplatelet therapy (DAPT), usually including acetyl salicylic acid (aspirin) plus platelet P2Y12 receptor inhibitors is an important part of that therapy. The careful balance between the protective effect regarding thrombotic/ischemic events and the risk of bleeding is an important task of the attending physician. Apart of the standard dosing regiments, in some of the cases a judgment regarding shortened or prolonged DAPT, as its de-escalation is mandatory. To present the causes and the way of application of that individualized approach in patients with PCI is the aim of this review. 
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
